Insmed names Will Lewis president and CEO

Tuesday, September 11, 2012

Monmouth Junction, N.J.-based Insmed, a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, has appointed Will Lewis president and CEO, effective immediately.

[Read More]

FDA lifts hold on Insmed’s Arikace

Friday, January 20, 2012

The FDA has lifted the clinical hold previously placed on Insmed’s Arikace (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease. However, Insmed is still engaged in discussions with the FDA regarding the clinical hold placed on Arikace in cystic fibrosis (CF) patients with Pseudomonas lung infections.

[Read More]

Insmed names Drucker senior VP

Wednesday, July 20, 2011

Insmed has named Andrea Holtzman Drucker, J.D., senior vice president, general counsel and corporate secretary, a newly created position. She will provide strategic legal and business advice for various operational aspects of the company.

[Read More]